Insights On Upstream Manufacturing

  1. Krakatoa® K500: A Seismic Shift In Media And Buffer Consumption 2/24/2026

    Learn how point-of-use media manufacturing delivers 30-50% cost savings while eliminating cold chain logistics, improving consistency, and accelerating advanced therapy production timelines.

  2. Steady & Stable From Lab To Launch: Seamless Scale-Up With The First And Only GMP Transfection Stabilizer 2/24/2026

    Learn how extended transfection stability windows and reduced complex volumes solve critical scale-up challenges in AAV and lentivirus manufacturing at 1000+ liter production scales.

  3. Avoiding Common Real-World Pitfalls In Viral Clearance Studies 2/24/2026

    Viral clearance studies face regulatory uncertainty, process limits, timeline pressure, and design challenges, demanding phase‑appropriate, flexible strategies for reliable outcomes.

  4. mRNA Manufacturing With Fed-Batch In Vitro Transcription 2/13/2026

    A milliliter-scale approach to IVT optimization reveals how controlled feeding, precise pH management, and real-time monitoring can boost mRNA yield and streamline scale-up to larger bioreactor volumes.

  5. A Comprehensive Solution For Adventitious Agent Testing 2/13/2026

    Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.

  6. A Faster, More Sensitive Approach To Virus Detection 2/13/2026

    Discover a faster, more sensitive approach to rodent virus detection that offers a targeted NGS workflow to help uncover contaminants traditional assays may miss.

  7. CHO K1 Cell Culture Process Intensification For Enhanced Production Of IgG mAbs 2/12/2026

    Discover how our optimized CHO K1 cell lines achieved up to an 80% increase in titer while maintaining product quality through molecule-specific process development strategies.

  8. The Science Of Cell Line Development For Biologics 2/12/2026

    Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success.

  9. Flexibility Or Scale? Navigating The Single Use Vs. Stainless Steel Debate 2/12/2026

    Explore how to choose between single‑use and stainless‑steel bioreactors, outlining key advantages, limitations, and long‑term considerations essential for successful biologics scale‑up.

  10. Integrated Upstream And Downstream Strategies For Robust mAb Manufacturing 2/5/2026

    Process robust mAb production requires understanding scale dependent cell environments, leveraging predictive models, and pursuing data driven control to minimize variability, optimize quality, and ensure reliable technology transfer across biomanufacturing scales.